Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that the European Commission has granted marketing authorization for Enrylaze® for use as a component of a...

Related Keywords

Italy ,Milano ,Lombardia ,Dublin ,Ireland ,Liechtenstein ,Norway ,Bicocca ,Sicilia ,Monza ,Iceland ,Canada ,United States ,Carmelo Rizzari ,Andrean Flynn ,Kristin Bhavnani ,Robert Iannone ,Nasdaq ,Children Oncology Group ,European Union Member States ,Drug Administration ,European Union ,Public Health ,Jazz Pharmaceuticals ,Prnewswire Jazz Pharmaceuticals ,Union Register ,Department Of Pediatrics ,Leukemia Foundation ,European Commission ,University Of Milano ,National Cancer Institute ,Professor Carmelo Rizzari ,Pediatric Hematology Oncology Unit ,Oncology Group ,Product Characteristics ,Acute Lymphoblastic Leukemia ,Lymphoblastic Lymphoma ,Strategic Brand ,Pediatr Blood ,Updated September ,Treasure Island ,Updated January ,Practice Guidelines ,Global Burden ,Disease Study ,Markets ,